Mesa Laboratories (MLAB) Lowered to C at TheStreet

TheStreet downgraded shares of Mesa Laboratories (NASDAQ:MLAB) from a b- rating to a c rating in a research report sent to investors on Wednesday.

Other equities research analysts have also issued reports about the company. Zacks Investment Research raised Mesa Laboratories from a strong sell rating to a hold rating in a research report on Tuesday, January 9th. BidaskClub raised Mesa Laboratories from a sell rating to a hold rating in a research report on Wednesday.

Shares of Mesa Laboratories (NASDAQ MLAB) traded up $0.94 during midday trading on Wednesday, reaching $133.50. The company’s stock had a trading volume of 885 shares, compared to its average volume of 18,561. The company has a current ratio of 2.37, a quick ratio of 1.97 and a debt-to-equity ratio of 0.58. The company has a market cap of $504.22, a price-to-earnings ratio of -131.21 and a beta of 0.52. Mesa Laboratories has a 1-year low of $117.58 and a 1-year high of $169.80.

Mesa Laboratories (NASDAQ:MLAB) last issued its earnings results on Monday, November 6th. The medical instruments supplier reported $0.60 earnings per share for the quarter, missing the Zacks’ consensus estimate of $0.64 by ($0.04). The firm had revenue of $22.95 million for the quarter, compared to the consensus estimate of $25.50 million. Mesa Laboratories had a negative net margin of 3.82% and a positive return on equity of 9.20%. equities research analysts anticipate that Mesa Laboratories will post 2.42 earnings per share for the current year.

The company also recently announced a quarterly dividend, which will be paid on Thursday, March 15th. Shareholders of record on Wednesday, February 28th will be given a dividend of $0.16 per share. This represents a $0.64 dividend on an annualized basis and a yield of 0.48%. The ex-dividend date is Tuesday, February 27th. Mesa Laboratories’s dividend payout ratio (DPR) is presently -64.00%.

In other Mesa Laboratories news, Director John Bradley Schmieder sold 3,000 shares of Mesa Laboratories stock in a transaction on Thursday, February 8th. The stock was sold at an average price of $132.27, for a total transaction of $396,810.00. Following the completion of the sale, the director now directly owns 77,869 shares of the company’s stock, valued at approximately $10,299,732.63. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Insiders own 15.70% of the company’s stock.

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Capital Analysts LLC bought a new position in shares of Mesa Laboratories in the 3rd quarter worth $128,000. SG Americas Securities LLC bought a new position in shares of Mesa Laboratories in the 3rd quarter worth $131,000. Voya Investment Management LLC bought a new position in shares of Mesa Laboratories in the 2nd quarter worth $221,000. Westfield Capital Management Co. LP bought a new position in shares of Mesa Laboratories in the 3rd quarter worth $239,000. Finally, Timber Hill LLC bought a new position in shares of Mesa Laboratories in the 3rd quarter worth $298,000. 71.29% of the stock is owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION WARNING: This story was originally published by Community Financial News and is the property of of Community Financial News. If you are reading this story on another publication, it was stolen and republished in violation of U.S. and international copyright & trademark laws. The correct version of this story can be read at https://www.com-unik.info/2018/02/09/mesa-laboratories-mlab-lowered-to-c-at-thestreet.html.

Mesa Laboratories Company Profile

Mesa Laboratories, Inc is focused primarily on quality control products and services. The Company operates through four segments: Instruments, Continuous Monitoring, Biological Indicators and Cold Chain. The Instruments Division designs, manufactures and markets quality control instruments and disposable products.

Receive News & Ratings for Mesa Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mesa Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit